Your browser doesn't support javascript.
loading
Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.
Rabasco Meneghetti, Asier; Zwanenburg, Alex; Linge, Annett; Lohaus, Fabian; Grosser, Marianne; Baretton, Gustavo B; Kalinauskaite, Goda; Tinhofer, Ingeborg; Guberina, Maja; Stuschke, Martin; Balermpas, Panagiotis; von der Grün, Jens; Ganswindt, Ute; Belka, Claus; Peeken, Jan C; Combs, Stephanie E; Böke, Simon; Zips, Daniel; Troost, Esther G C; Krause, Mechthild; Baumann, Michael; Löck, Steffen.
Affiliation
  • Rabasco Meneghetti A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Zwanenburg A; Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
  • Linge A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Lohaus F; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Grosser M; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Baretton GB; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Kalinauskaite G; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tinhofer I; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Guberina M; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Stuschke M; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Balermpas P; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • von der Grün J; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Ganswindt U; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Belka C; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Peeken JC; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Combs SE; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Böke S; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Zips D; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Troost EGC; Tumour- and Normal Tissue Bank, University Cancer Centre (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Krause M; German Cancer Consortium (DKTK) Partner Site Berlin, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Baumann M; Department of Radiooncology and Radiotherapy, Charité University Medicine Berlin, Berlin, Germany.
  • Löck S; German Cancer Consortium (DKTK) Partner Site Berlin, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sci Rep ; 12(1): 16755, 2022 10 06.
Article in En | MEDLINE | ID: mdl-36202941
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) may benefit from personalised treatment, requiring biomarkers that characterize the tumour and predict treatment response. We integrate pre-treatment CT radiomics and whole-transcriptome data from a multicentre retrospective cohort of 206 patients with locally advanced HNSCC treated with primary radiochemotherapy to classify tumour molecular subtypes based on radiomics, develop surrogate radiomics signatures for gene-based signatures related to different biological tumour characteristics and evaluate the potential of combining radiomics features with full-transcriptome data for the prediction of loco-regional control (LRC). Using end-to-end machine-learning, we developed and validated a model to classify tumours of the atypical subtype (AUC [95% confidence interval] 0.69 [0.53-0.83]) based on CT imaging, observed that CT-based radiomics models have limited value as surrogates for six selected gene signatures (AUC < 0.60), and showed that combining a radiomics signature with a transcriptomics signature consisting of two metagenes representing the hedgehog pathway and E2F transcriptional targets improves the prognostic value for LRC compared to both individual sources (validation C-index [95% confidence interval], combined: 0.63 [0.55-0.73] vs radiomics: 0.60 [0.50-0.71] and transcriptomics: 0.59 [0.49-0.69]). These results underline the potential of multi-omics analyses to generate reliable biomarkers for future application in personalized oncology.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hedgehog Proteins / Head and Neck Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2022 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hedgehog Proteins / Head and Neck Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2022 Type: Article Affiliation country: Germany